K

Karim Fizazi

Université de Lille

ORCID: 0000-0002-6068-9474

Publishes on Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications, Prostate Cancer Diagnosis and Treatment. 1.6k papers and 84.6k citations.

PubIndex Score98Top 2%How it's scored

1.6kPublications

84.6kTotal Citations

First publication: 1996First senior author: 2001

Prostate Cancer Treatment and Research Radiopharmaceutical Chemistry and Applications Prostate Cancer Diagnosis and Treatment Cancer, Lipids, and Metabolism Cancer Genomics and Diagnostics

Top publicationsby citations

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Tomasz M. Beer, Bertrand Tombal, Andrew J. Armstrong et al.|New England Journal of Medicine|2014

Cited by 3k

Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

Charles J. Ryan, Dana E. Rathkopf, Matthew R. Smith et al.|New England Journal of Medicine|2012

Cited by 2.8k

Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

Howard I. Scher, Andrew J. Armstrong, Michael J. Morris et al.|Journal of Clinical Oncology|2016

Cited by 1.6k

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Karim Fizazi, Johann S. de Bono, Howard I. Scher et al.|The Lancet Oncology|2012

Cited by 1.4k

Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

Charles J. Ryan, Dana E. Rathkopf, Matthew R. Smith et al.|The Lancet Oncology|2015

Cited by 1.4k